- FDA Initiative
- Outcome Measures
- Performance Measures
- Treatment Guidelines
Clinical Trial Guidelines
A diverse group of about 90 OARSI members have begun work on an OARSI initiative to update the 1996 recommendations from a task force of the OARS on the design and conduct of clinical trials in OA. Updating this document was felt to be particularly timely in light of the recent OARSI Food and Drug Administration (FDA) Initiative resulting in publication of multiple articles from the OARSI FDA Initiative Working Groups in the May 2011 special edition ofOsteoarthritis and Cartilage.
The aims of this initiative include the following:
- Define scope and format of updated document(s) in light of new areas of relevance to OA clinical trials, such as methodologic issues in post-traumatic OA, intra-articular therapies, non-pharmacologic therapies, surgical clinical trials, community-based interventions, and prevention trials
- Disseminate results as one or more documents inOsteoarthritis and Cartilage, on the OARSI website, and elsewhere depending upon desires of OARSI Board and other appropriate organizations
The manuscript will be published in late April, 2015.
Biomarkers- Improve Prognosis and Treatment of Osteoarthritis
The Biomarkers Consortium, a public-private partnership managed by the Foundation for the National Institutes of Health (FNIH), announced that significant progress is being made in the OARSI endorsed FNIH Osteoarthritis (OA) Biomarkers Project, which seeks to improve clinical outcomes for nearly 30 million people in the US living with OA of the knee and for those at risk for developing the disease. The OA Biomarkers Project is being led by two world-renowned scientists from OARSI, Dr. David Hunter at the University of Sydney and Dr. Virginia Byers Kraus at Duke University. The Biomarkers Consortium combines expertise from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), biotech and pharmaceutical companies, academia, and disease-focused non-profit organizations